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Abstract
Background: The purpose of this study was to assess the functional effects and acceptability of rocker-soled shoes
that were designed to relatively “unload” the calf muscles during walking in people with calf claudication due to
peripheral arterial disease.
Methods: In this randomised AB/BA crossover trial, participants completed two assessment visits up to two weeks
apart. At each visit, participants completed walking tests whilst wearing the unloading shoes or visually-similar
control shoes. At the end of the second visit, participants were given either the unloading or control shoes to use
in their home environment for 2 weeks, with the instruction to wear them for at least 4 h every day. The primary
outcome was 6-min walk distance. We also assessed pain-free walking distance and gait biomechanical variables
during usual-pace walking, adverse events, and participants’ opinions about the shoes. Data for continuous
outcomes are presented as mean difference between conditions with corresponding 95% confidence interval.
Results: Thirty-four participants (27 males, mean age 68 years, mean ankle-brachial index 0.54) completed both
assessment visits. On average, the 6-min walk distance was 11 m greater when participants wore the control shoes
(95% CI -5 to 26), whereas mean pain-free walking distance was 7 m greater in the unloading shoes (95% CI -17 to
32). Neither of these differences were statistically significant (p = 0.18 and p = 0.55, respectively). This was despite
the unloading shoes reducing peak ankle plantarflexion moment (mean difference 0.2 Nm/kg, 95% CI 0.0 to 0.3)
and peak ankle power generation (mean difference 0.6 W/kg, 95% CI 0.2 to 1.0) during pain-free walking. The
survey and interview data was mixed, with no clear differences between the unloading and control shoes.
Conclusions: Shoes with modified soles to relatively unload the calf muscles during walking conferred no
substantial acute functional benefit over control shoes.
Trial registration: Clinicaltrials.gov, Trial Registration Number: NCT02505503, First registered 22 July 2015.
Keywords: Peripheral arterial disease, Foot orthoses, Gait, Cross-over studies
Background
Intermittent claudication, a common symptom of lower-
limb peripheral arterial disease (PAD), is defined as leg
pain or discomfort in the calf of one or both legs that
occurs during walking and is relieved within 10 min of
rest. Although intermittent claudication is not directly
life threatening, it can markedly reduce quality of life by
limiting walking and other activities of daily living [1].
Qualitative research has identified that the intensity of
claudication pain experienced during walking is influ-
enced by several factors, such as the surface walked on
(e.g., grass versus tarmac), the incline and speed of
walking, and the type of shoes worn [2]. Regarding the
latter, it is thought that factors such as the pitch of the
shoe and the amount of support that a shoe gives to the
ankle joint may influence the metabolic demands of the
calf musculature during walking, and thus the speed of
occurrence and intensity of claudication pain [3]. There-
fore, if specific shoes could be designed to relatively
“unload” the calf musculature during walking, then they
might be a useful adjunct treatment for people with calf
claudication.
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Empirical evidence on footwear interventions for inter-
mittent claudication is mixed and sparse [3–5]. A recent
pilot study indicated that pain-free walking distance was
increased, and the intensity of claudication pain reduced,
when participants with calf claudication (n = 8) walked
at their self-selected walking speed in a specially-
designed, rocker-soled shoe compared with when walk-
ing in an un-adapted control shoe [3]. The rocker sole
used was shaped to place the foot in a relatively plantar-
flexed position during the stance phase of gait while
simultaneously reducing sagittal plane ankle range of
motion. Previous testing in healthy adults (n = 12) had
suggested a calf-unloading effect of these shoes; peak
ankle plantarflexion moment during walking being
reduced by 25% versus control [6]. The present study
sought to further explore the efficacy and acceptability
of similar rocker-soled unloading shoes in a larger
sample of people with calf claudication. The primary
objective was to assess the immediate effect of wearing
the shoes on walking distances and gait. We also sought
participants’ opinions about the shoes following a
2-week period of use in the home environment.
Methods
Study design and setting
YORVIC (York study of unloading shoes for vascular
intermittent claudication) was a single-centre rando-
mised AB/BA crossover trial with a 2-week observational
follow-up. Participants were recruited from vascular
clinics at York Hospital, and all assessments were con-
ducted at York St John University. Following a screening
visit, participants completed two assessment visits up to
2 weeks apart. At each assessment visit, participants
completed three standardised walking tests whilst wear-
ing either the unloading shoes or visually-similar control
shoes, the order of which was randomly assigned. At the
end of the second assessment visit, participants were
given either the unloading or control shoes to use in
their home environment for 2 weeks, with the instruc-
tion to wear them for at least 4 h every day. At the end
of this period, participants returned the shoes and a
completed survey about them. A sub-sample of partici-
pants was also interviewed about their experiences of
using the shoes. Participants were able to claim up to
£15 per visit towards travel expenses. The study was
approved by the NRES Committee for Yorkshire & The
Humber - Leeds West (Ref: 15/YH/0107), and prospect-
ively registered (ClinicalTrials.gov: NCT02505503). Written
informed consent was obtained from participants prior to
enrolment.
Participants
Inclusion criteria were: aged ≥16 years; stable symptoms
of intermittent claudication for ≥3 months; resting
ankle-brachial index ≤0.9 and/or imaging evidence of
PAD; pain-free walking distance <250 m on 6-min walk
test with ambulation limited primarily by calf claudica-
tion (assessed at screening visit), and; able to read and
speak English and provide written informed consent. We
excluded people with: absolute contraindications to
exercise testing (as defined by the American College of
Sports Medicine [7]); critical limb ischemia; lower-limb
amputation; co-morbidities that limit walking to a
greater extent than intermittent claudication (e.g., severe
knee osteoarthritis); ambulation limited by claudication
in regions other than the calf; major ankle or foot path-
ology, and; current or previous (within 6 months) use of
shoe inserts, knee or ankle braces or customised shoes
prescribed by a health professional.
Interventions
The unloading and control shoes were produced and
supplied by an established shoe manufacturer (Chaneco;
www.chaneco.co.uk). Shoe size was assessed during the
screening visit, and shoes were ordered after eligibility
had been confirmed. The unloading shoe was a trainer-
type shoe with a black leather upper section, laces, and a
specially-designed rocker sole (Fig. 1a). The rocker soles,
which were manually shaped according to the specifica-
tions of the patent that is owned by the University of
York (Patent no.: GB2458741B), comprised three circu-
lar curves with arc centres that are positioned at the
anatomical ankle, hip and knee, respectively (assuming a
vertical lower limb), and so forming a posteriorly-placed
apex to the rocker shape. This is designed to influence
the line of action of the ground reaction force to pass
Fig. 1 Unloading shoes (a) and control shoes (b)
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close to the anatomical joint centres and so reduce the
moments needed to be generated for ambulation by the
muscles acting across those joints in the lower limb.
Additionally, it is designed to place the ankle into a
relatively plantarflexed position where the ankle plantar-
flexors use less energy than, for instance, when placed in
dorsiflexion. This is because it also increases the lever
arm between the Achilles tendon and the ankle joint; so
making propulsion, and therefore calf muscle power
generation, more efficient. It is also intended to unload
the calf muscles by providing a simultaneous reduction
in ankle range of motion in relative plantarflexion but
still moving with a near-normal trajectory. To facilitate
participant blinding, the control shoes were made to be
similar in appearance to the unloading shoes (Fig. 1b).
These shoes had the same upper section as the unload-
ing shoes, but a different rocker sole. Here, the apex of
the sole was anteriorly-placed, which is not designed to
place the ankle in relative plantarflexion during stance
phase of gait. Participants were allowed to habituate to
wearing each pair of shoes for 5 min before commencing
the first walking test.
Assessment procedures and outcome measures
Both assessment visits involved three walking tests that
were separated by 20-min periods of seated rest: (i) a
6-min corridor walk test to quantify 6-min walk distance
(6MWD) [8], (ii) a usual-pace walk test to measure pain-
free walking distance, and (iii) a “figure-of-8” walk test
during which gait biomechanical parameters were quan-
tified as described previously [9]. Heart rate (via telem-
etry: Polar T31 transmitter with Polar FT1 watch, Polar
Electro, Oy, Finland), blood pressure (Omron M6 Com-
fort, Omron Healthcare Europe B.V., Hoofddorp, The
Netherlands), and ratings of perceived exertion (Borg
6–20 scale [10]) and leg pain (Borg CR-10 scale [10])
were recorded before and immediately after each test.
All participants had a leg pain score of 0 before com-
mencing the next test. For the 6-min walk test, we used
a 30-m straight corridor and standardised instructions
[11], which included to walk as far as possible within the
6 min. The same course was used for the usual-pace test.
The figure-of-8 test was conducted in a gait laboratory.
A figure-of-8 was chosen to minimise the potential for
fatigue that might have been be caused through partici-
pants solely performing all clockwise or all counterclock-
wise turns. Reflective markers were positioned on
anatomical landmarks of the lower extremities using
double-sided sticky tape to allow 3D motion analysis [9].
Participants were instructed to walk at their usual pace
along a figure-of-8 circuit, without slowing down, for a
maximum of 12 min. A force plate (9281EA, Kistler,
Germany) positioned in the central straight portion of
the course captured kinetic data. The participants were
naïve to the force plate, to help ensure a natural walking
gait. Infra-red 3D optical motion analysis cameras
(Oqus, Qualisys, Sweden) captured kinematic data each
time a participant approached and passed over the force
plate. Kinetic and sagittal plane kinematic data were
exported to Visual 3D motion analysis software (C
Motion, Rockville, MD, USA) for processing and ana-
lysis. Inverse dynamics were used to determine joint
moments and powers. Participants indicated when they
experienced the onset of claudication pain and contin-
ued walking until pain prevented them walking further.
Time-distance variables used to identify gait differences
between the two shoe conditions during pain-free walk-
ing were walking speed, step length, step cadence, and
time in stance phase, swing phase, and double support
(% of gait cycle). The potential calf unloading effect of
the adapted shoes was also explored using the following
variables for the most affected limb: ankle range of mo-
tion, peak plantarflexion angle, peak plantarflexion mo-
ment (in Nm per kg body mass), and peak plantarflexion
power (in W per kg body mass).
After completing the second assessment visit, all partici-
pants were given the pair of shoes that they wore during
that visit to wear for 2 weeks. During this period, the par-
ticipants were instructed to wear the allocated shoes as
much as possible every day, with a minimum target of 4 h
per day [12]. On completing the 2-week period, the partic-
ipants were asked to return the shoes along with a com-
pleted survey about them. In the survey, participants were
asked to estimate, on average, how many hours per day
they wore the shoes. They also rated the overall level of
shoe comfort using an 11-point (0–10) numeric rating
scale (with terminal descriptors of ‘extremely uncomfort-
able’ and ‘extremely comfortable’), and perceived changes
in walking ability and physical activity using 5-point (1–5)
scales (with terminal descriptors of ‘much worse’ to ‘much
better’ and ‘much less physically active’ to ‘much more
physically active’, respectively). Finally, participants re-
corded any benefits, negative aspects, and untoward med-
ical events related to the shoes.
A sub-sample of 12 participants also undertook a
telephone-based interview to share their thoughts about
the shoes. Purposive sampling was used according to the
following criteria: shoe type (unloading and control), age
(above and below 65 years), sex, and walking ability
(6MWD above and below 350 m). The interviewer sought
feedback regarding factors affecting shoe usage, benefits
and negative consequences of wearing the shoes, and the
design of the shoes. All interviews were audio-recorded,
transcribed, and analysed to identify themes.
Adverse events
We recorded all serious adverse events (regardless of
cause), and all non-serious adverse events that were
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believed to have occurred as a result of performing a
study assessment, or from using the study shoes. The
latter are subsequently termed ‘adverse device effects’.
Randomisation, allocation concealment and blinding
The order of testing for each participant (i.e., unloading
shoes first then control shoes, or vice versa) was deter-
mined using a computer-generated randomisation se-
quence created by a statistician at York Trials Unit, who
was not otherwise involved in the study. Blocked ran-
domisation with a block size of 8 was used to ensure
that the overall order of testing was balanced (ratio 1:1).
The allocations were blinded (i.e. labelled AB and BA)
before being passed to the trial statistician. Once a par-
ticipant had completed the screening visit, an investiga-
tor emailed the trial statistician who assigned the
participant to the next available allocation.
Participants were blinded to allocation by using control
shoes that were visually-similar to the unloading shoes
and by stating in the participant information sheet that
the study was investigating two different types of shoes,
rather than comparing normal and adapted shoes. Our at-
tempt to blind the outcome assessor was unsuccessful be-
cause they were not naïve to the true purpose of the study
and therefore could tell which shoe was the unloading
shoe when preparing the participant for the gait analysis.
However, the use of standardised testing procedures and
objective outcomes (e.g., 6MWD) ensured that the risk of
detection bias is low. The researcher overseeing data entry
and the statistician remained blinded until the analysis
was complete.
Sample size
The primary outcome was 6MWD measured in metres.
The cross-over ANOVA square root of the mean
squared error for 6MWD was found to be 30 m in a re-
cent trial [13]. A mean difference of 25 m has been sug-
gested as the minimum clinically important difference
[14]. Using these values at 90% power and 2-sided 5%
significance level in a cross-over design would require
34 participants. Therefore, recruitment stopped once
6MWD had been collected at both assessment visits for
34 participants.
Statistical analysis
Formal analyses were conducted following the principles
of intention-to-treat with participant’s outcomes ana-
lysed according to their original, randomised testing
order irrespective of the order that they actually received
the shoes, where data were available. Analyses were
undertaken in Stata v13 using two-sided statistical tests
at the 5% significance level. Participant baseline data are
summarised descriptively overall and by testing order
(AB or BA) both as randomised and as analysed in the
primary analysis. No formal statistical comparisons
between testing orders were undertaken on baseline
data. To allow for a possible period effect, analysis of the
6MWD was via a two-sample t-test to compare the dif-
ference between assessment 1 and assessment 2 for the
two sequences. Dividing the resultant difference (and
corresponding 95% confidence limits) by two gives an
estimate of the treatment effect (i.e., A minus B) and
95% CI. Pain-free walking distance at usual pace was
analysed in the same manner. Kinetic, kinematic and
temporal-spatial measures of gait were taken at each
assessment visit and calculated for each participant when
pain free, at the onset of pain, and at absolute pain. The
difference between the measure as assessed at visit 1 and
visit 2 was calculated for each participant at each point
in time (pain free, pain onset, and absolute pain). These
three differences were modelled using a covariance
pattern mixed model, with sequence allocation (AB or
BA), time and an allocation-by-time interaction as fixed
effects and participant as a random effect. The mean dif-
ferences (and 95% CI) between the two sequences were
extracted for the pain-free, onset of pain, and absolute
pain time points, and divided by two to obtain an esti-
mate of the treatment effect A-B. Only the data for
pain-free walking is presented in this manuscript; all
other gait data will be published elsewhere.
Results
Between August 2015 and August 2016, 71 patients were
approached to participate in the trial, of whom 42 (59%)
were screened and 37 (52%) were randomised (Fig. 2):
18 were allocated to the sequence AB (control, unload-
ing) and 19 to BA (unloading, control). Two participants
withdrew from the trial before the first assessment visit,
and one participant withdrew during the second assess-
ment visit due to an adverse device effect of feeling un-
balanced whilst wearing the shoes; resulting in 34
participants being included in the primary analysis.
Characteristics of the 37 randomised participants and
the 34 analysed participants are presented in Table 1.
The majority of participants (as randomised) were male
(n = 27, 73%), and the mean age was 67 years (range 31
to 86). All participants had experienced symptoms of
intermittent claudication for at least 4 months (median
16 months) at screening, and had a resting ankle-
brachial index for the most-affected limb of between
0.25 and 0.89 (mean 0.53, SD 0.14). The mean distance
walked during the 6-min walk test at screening was
373 m (SD 100).
Effects of the unloading shoes on walking ability and gait
The first assessment visit took place between 3 and
26 days after screening (median 12 days for the AB
group and 11 days for the BA group), and the second
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visit up to 14 days after the first (median 7 days for the
AB group and 5 days for the BA group). All participants
received their footwear in the allocated order, except for
one participant allocated to BA, who was tested in the
order AB (control, unloading) by mistake.
The unadjusted mean 6MWD was 381 m (SD 99) for
the control shoe condition (n = 35) and 372 m (SD 94)
for the unloading shoe condition (n = 34). The analysis
accounting for a possible period effect indicated that the
6MWD was on average 11 m greater when participants
wore the control shoes (95% CI -5 to 26; Table 2); how-
ever, this was not statistically significant (p = 0.18). The
unadjusted mean pain-free walking distance during
usual-pace walking was 160 m (SD 88) for the control
condition (n = 35) and 164 m (SD 132) for the unloading
condition (n = 34). On average, participants walked 7 m
further before experiencing pain when wearing the
unloading shoes (95% CI -17 to 32; Table 2). Again, this
difference was not statistically significant (p = 0.55).
Mean rating of perceived exertion at the end of the
6-min walk test in the first assessment was 12.1 (i.e.,
“light” to “somewhat hard”; SD 2.0) in the AB group and
12.1 (SD 1.9) in the BA group. In the second assessment,
it was 12.4 (SD 1.9) in the AB group and 12.0 (SD 2.6)
in the BA group. The mean difference between condi-
tions (control minus unloading) was −0.1 (95% CI -0.7
to 0.6). Mean rating of leg pain at the end of the 6-min
walk test in the first assessment was 5.1 (i.e., “strong”;
SD 2.5) in the AB group and 5.0 (SD 2.2) in the BA
group. In the second assessment, it was 4.6 (SD 2.2) in
the AB group and 5.3 (SD 2.1) in the BA group. The
mean difference was 0.5 (95% CI -0.1 to 1.1). Heart rate
responses were similar for both conditions (data not
presented).
Fig. 2 Flow of participants through the trial
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Gait variables for pain-free walking are presented in
Table 3. The temporal-spatial variables (e.g., walking
speed, step length, step cadence) did not differ substan-
tially between conditions. This was also the case for
ankle range of motion (mean difference 0.8°; 95% CI -0.5
to 2.2). However, relative to control, the unloading shoes
caused a reduction in the peak values of plantarflexion
angle (mean difference 2.5°; 95% CI 1.3 to 3.7), ankle
plantarflexion moment (mean difference 0.2 Nm/kg,
95% CI 0.0 to 0.3), and ankle power generation (mean
difference 0.6 W/kg, 95% CI 0.2 to 1.0).
Adverse events
There were four non-serious adverse device effects: three
for the unloading shoes and one for the control shoes.
The adverse device effects for the unloading shoes were
foot and ankle pain (n = 1), perceived difficulty in
balancing (n = 1), and irritation of a pre-existing bunion
(n = 1). For the control shoes, one participant reported
experiencing ‘foot discomfort’. There was also one
protocol-related, non-serious adverse event. Here, a par-
ticipant experienced mild bruising to the medial aspect of
the knee upon removal of the reflective marker that was
used for the gait analysis.
Survey and interview responses
Thirty-one (91%) of the 34 participants who attended
their second assessment visit were given a pair of shoes
(13 unloading, 18 control) to use in their home environ-
ment for 2 weeks, of whom 29 (12 unloading, 17 con-
trol) returned a completed survey at the end of this
period. Twelve participants (7 male, 5 female; 6 unload-
ing, 6 control) were also interviewed after the 2-week
home-wear period. Survey responses indicated a mean
daily wear times of 4.8 h (SD 2.4) for the control shoes
(n = 17) and 3.8 h (SD 1.8) for the unloading shoes (n = 11,
Table 1 Baseline characteristics of the participants as randomised, and as included in the primary analysis
Characteristic As randomised As analysed
AB (n = 18) BA (n = 19) Total (n = 37) AB (n = 15) BA (n = 19) Total (n = 34)
Age, years, mean (SD) 67.3 (14.9) 66.5 (10.2) 66.9 (12.5) 70.6 (8.8) 66.5 (10.2) 68.3 (9.7)
Gender, male 12 (67) 15 (79) 27 (73) 12 (80) 15 (79) 27 (79)
Ethnic origin, White British 18 (100) 19 (100) 37 (100) 15 (100) 19 (100) 34 (100)
Ankle-brachial index, mean (SD) 0.52 (0.13) 0.54 (0.16) 0.53 (0.14) 0.53 (0.13) 0.54 (0.16) 0.54 (0.14)
Duration of claudication symptoms,
months, median (range)
15 (6, 125) 30 (4, 249) 16 (4, 249) 15 (6, 125) 30 (4, 249) 18 (4, 249)
Body mass index, kg/m2, mean (SD) 27.8 (4.2) 28.4 (4.8) 28.1 (4.5) 28.8 (3.8) 28.4 (4.8) 28.5 (4.4)
Heart rate, beats/min, mean (SD) 73 (12) 72 (11) 72 (11) 75 (12) 72 (11) 73 (11)
Systolic blood pressure, mmHg, mean (SD) 158 (21) 143 (25) 150 (24) 156 (22) 143 (25) 149 (24)
Diastolic blood pressure, mmHg, mean (SD) 83 (12) 81 (10) 82 (11) 84 (13) 81 (10) 82 (11)
Current smoker 4 (22) 2 (10) 6 (16) 4 (27) 2 (10) 6 (18)
Previous smoker 12 (67) 14 (74) 26 (70) 11 (73) 14 (74) 25 (73)
Never smoked 2 (11) 3 (16) 5 (14) 0 (0) 3 (16) 3 (9)
Diabetes mellitus 4 (22) 5 (26) 9 (24) 4 (27) 5 (26) 9 (27)
Hypertension 14 (78) 13 (68) 27 (73) 12 (80) 13 (68) 25 (74)
Hyperlipidaemia 14 (78) 14 (74) 28 (76) 13 (87) 14 (74) 27 (79)
Chronic obstructive pulmonary disease 1 (6) 2 (11) 3 (8) 0 (0) 2 (11) 2 (6)
Arthritis 2 (11) 2 (11) 4 (11) 1 (7) 2 (11) 3 (9)
History of angina 2 (11) 6 (32) 8 (22) 2 (13) 6 (32) 8 (24)
History of myocardial infarction 0 (0) 6 (32) 6 (16) 0 (0) 6 (32) 6 (18)
History of stroke/transient ischaemic attack 3 (17) 2 (11) 5 (14) 3 (20) 2 (11) 5 (15)
Anti-platelet/Anti-coagulant medication 13 (72) 14 (74) 27 (73) 12 (80) 14 (74) 26 (77)
Lipid-lowering medication 14 (78) 13 (68) 27 (73) 13 (87) 13 (68) 26 (77)
Anti-diabetic medication 3 (17) 4 (21) 7 (19) 3 (20) 4 (21) 7 (21)
Beta-blockers 3 (17) 4 (21) 7 (19) 1 (7) 4 (21) 5 (15)
Other anti-hypertensive medication 13 (72) 14 (74) 27 (73) 11 (73) 14 (74) 25 (74)
6-min walk distance, metres, mean (SD) 372 (92) 367 (106) 369 (98) 382 (95) 367 (106) 373 (100)
Data are number (%) unless otherwise stated. AB, control then unloading; BA, unloading then control
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one missing data point). The interview data also showed
similar shoe usage, with responses ranging 3 to 7 h per day;
however, one participant reported that she stopped using
the unloading shoes after three days because they had irri-
tated her bunion. Median survey comfort ratings were 8
(interquartile range (IQR) 5–10) and 6 (IQR 3–10) for the
control and unloading shoes, respectively. All survey
respondents and 11 out of 12 interviewees perceived their
walking ability as unchanged or better during the home-
wear period. In the control group, six survey respondents
(35%) and two interviewees (33%) reported an improve-
ment versus six survey respondents (50%) and three inter-
viewees (50%) in the unloading group. However, fewer
people reported that their physical activity had increased
Table 2 Walking distance results
Outcome measure Treatment sequence Treatment period Within-individual
difference: Control
minus unloading
1 2
6-min walk distance, metres AB
Sample size 16 15 15
Mean (SD) 386 (92) 374 (93) 16 (45)
BA
Sample size 19 19 19
Mean (SD) 371 (97) 376 (107) 5 (45)
Treatment effecta
Sample size – – 34
Mean (95% CI) – – 11 (−5 to 26)
p-value – – 0.18
Pain-free walking distance
during usual-pace walking,
metres
AB
Sample size 16 15 15
Mean (SD) 161 (106) 217 (178) −53 (81)
BA
Sample size 19 19 19
Mean (SD) 121 (55) 159 (72) 38 (60)
Treatment effecta
Sample size – – 34
Mean (95% CI) – – −7 (−32 to 17)
p-value – – 0.55
aEstimate of the difference between the control and the unloading shoes, accounting for a possible period effect
AB, control then unloading; BA, unloading then control
CI confidence interval, SD standard deviation
Table 3 Gait variables during pain-free walking
Variable Control Shoes A Unloading shoes B Mean differencea (95% CI)
Walking speed (m/s) 1.16 (0.26) 1.17 (0.26) −0.01 (−0.03 to 0.01)
Step length (m) 0.63 (0.11) 0.63 (0.11) −0.01 (−0.02 to 0.01)
Step cadence (steps/min) 110.0 (11.5) 109.7 (12.1) 0.4 (−0.9 to 1.6)
Stance phase (%) 64.2 (2.3) 63.9 (2.3) 0.3 (−0.1 to 0.7)
Swing phase (%) 35.7 (2.4) 36.0 (2.5) −0.3 (−0.8 to 0.2)
Double support (%) 28.5 (4.5) 28.1 (4.0) 0.3 (−0.3 to 1.0)
Ankle range of motion (°) 24.4 (3.6) 23.6 (3.4) 0.8 (−0.5 to 2.2)
Peak plantarflexion angle (°) 14.8 (3.2) 12.3 (2.9) 2.5 (1.3 to 3.7)
Peak plantarflexion moment (Nm/kg) 1.4 (0.2) 1.2 (0.4) 0.2 (0.0 to 0.3)
Peak ankle power generation (W/kg) 2.3 (0.8) 1.7 (0.8) 0.6 (0.2 to 1.0)
aAdjusted estimate of difference for control minus unloading using covariance pattern mixed model approach
Data are mean (SD) unless otherwise stated. Kinetic and kinematic data are for the most affected limb
CI confidence interval
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during the home-wear period: four survey respondents
(24%) and one interviewee (17%) from the control group
and three survey respondents (25%) and two interviewees
(33%) in the unloading group. From the survey, the most
commonly cited barriers to using the shoes were “lack of
comfort” (n = 3 [18%] vs. n = 2 [17%], respectively), “shoe
appearance” (n = 5 [29%] vs. n = 2 [17%], respectively), and
“impractical” (n = 2 [12%] vs. n = 3 [25%], respectively). The
interviews also gleaned mixed feedback about the comfort
and design of the shoes. Six participants (50%; three from
each group) reported the shoes as being comfortable, and
that they would be willing to pay between £30 and £60 for
them. However, three participants (1 control, 2 unloading)
found them to be uncomfortable. Four interviewees in the
unloading group commented on the heel being too big,
whereas only one person from the control group commen-
ted on size, describing the shoes as “bulky”. Recommenda-
tions on design features included having a boot style rather
than a shoe (n = 3), having Velcro instead of laces (n = 1),
and having a choice of colours (n = 2). All but one inter-
viewee (from the control group) expressed a willingness to
participate in a potential future study where participants
would be required to use the shoes over a 6-month period.
Example quotes are shown in Additional file 1.
Discussion
In this study, shoes with specially-designed rocker soles
to reduce calf load during walking offered no immediate
functional benefit when compared with control shoes in
people with calf claudication due to peripheral arterial
disease. The gait analysis data indicated that the rocker-
soled shoes did indeed unload the calves of claudication
patients during usual-pace, pain-free walking; however,
this did not translate into improved walking distances
during the standardised walking tests. Following the
2-week home-wear period, approximately one third of
participants using the control shoes and one half of par-
ticipants using the unloading shoes reported experien-
cing improved walking ability when wearing their
allocated shoes. There was mixed feedback regarding the
acceptability of the shoes; however, 11 out of 12 inter-
viewees reported they would be willing to taking part in a
longer-term shoe study, which suggests that patients are
interested in footwear as an intervention for claudication.
Our findings contrast that of previous limited research.
A smaller study of 21 people with calf claudication
showed that commercially-made, rocker-soled unloading
shoes acutely increased usual-pace walking ability, with
both the total distance walked and the distance at which
patients were initially bothered by symptoms being on
average 77 m (37%, p < 0.01) and 89 m (91%, p < 0.01)
further, respectively, compared with a standard shoe
condition [5]. The use of different walking assessments
prevents a direct comparison with our findings; however,
it is important to note that the “bothered distance” is
highly subjective (and thus has poor reliability), and that
the reported differences were largely explained by one
outlier participant who showed improvements of 710 m
and 850 m, respectively. A more recent study of 8
people with calf claudication also showed that unloading
shoes, which were similar to those used in the current
study, improved pain-free walking distance during usual-
pace walking by an average of 19 m (39%, p < 0.05) rela-
tive to an un-adapted control shoe [3]. Again, a direct
comparison cannot be made because of different walking
test procedures, but also because slightly different inter-
vention and control shoes were used. Nevertheless, this
previous study was limited by a small sample size and
lack of participant and tester blinding, which may have
biased the results. The aforementioned limitations in the
evidence base prompted the current investigation.
The current study was appropriately powered and
assessed walking ability at both usual and forced walking
paces. Despite the unloading shoes causing mean reduc-
tions in peak ankle plantarflexion moment and peak
ankle power generation of 14% and 26%, respectively,
the mean differences in walking distances between
conditions were trivial and in varied direction (pain-free
walking distance improved, 6MWD worsened; Table 2).
It is unclear why the beneficial effects of unloading shoes
on ankle biomechanics seen here and elsewhere [6] did
not translate to functional benefit. One possibility is that
5 min was not long enough for the participants to
habituate to wearing the different shoes. Although we
cannot rule this out, our approach was consistent with
what others have done previously [3, 5]. Alternatively, it
may be that the biomechanical effects were generally too
small to influence walking distances or that claudication
symptoms are not as strongly influenced by manipulat-
ing ankle biomechanics as we originally suspected. Inter-
estingly, the mean reduction in peak ankle plantarflexion
moment was smaller than that reported previously in
healthy younger adults (14% vs. 25%) [6]. This difference
may have been due to the slight alterations that were
made for intervention and control shoes in the present
study, e.g., the soles of the unloading shoes being made
less deep to increase acceptability to participants, and
the soles of the control shoes being “filled in” to facili-
tate participant blinding. However, given that the abso-
lute reduction in peak ankle power generation was of
similar magnitude to the difference previously reported
between claudication patients and healthy controls
(2.437 [SD 0.445] vs. 2.957 [SD 0.686], p < 0.01) [15], we
are surprised that changes in walking distances were not
observed. It is important to remember that there is no
such thing as a “biomechanically inert” shoe to use as a
placebo, and we are confident that the shoe design fea-
tures we selected were appropriate for assessing the
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functional effects of unloading shoes while maintaining
methodological rigor. Nevertheless, further research
would be useful to determine the magnitude of calf
unloading that is needed to observe an improved walk-
ing ability in different claudicants, and to see if engineer-
ing of the shoe can produce greater biomechanical
effects without compromising safety and acceptability.
Interestingly, the variable effects of footwear on the
walking ability of claudicants in the literature [3, 5], and
the fact that many of participants reported beneficial
effects of both shoe types during the 2-week home-wear
period, raises the possibility that some patients are more
responsive to biomechanical interventions than others.
Placebo effects likely explain at least some of the
reported benefits by survey respondents and inter-
viewees for both types of shoes. The reported benefits of
both shoe types might, however, also be related to other
characteristics that were common to both shoes. Both
were cushioned, lace-up shoes with flexible leather up-
pers, which for some participants may have represented
a significant improvement over their usual footwear.
Unfortunately, the usual footwear was not recorded.
In conclusion, the main finding from this study was
that the unloading shoes were relatively ineffective for
improving walking ability in people with calf claudica-
tion. Although this finding is disappointing, the concept
of a shoe reducing claudication pain remains good. The
mainstay of current treatment for intermittent claudica-
tion, after best medical therapy, is invasive intervention.
We have a duty to continue to explore non-invasive op-
tions in the management of claudication to compliment/
substitute the sporadic funding of supervised exercise
programmes [16]. Further preliminary studies are
needed to optimise shoe design and confirm clinical effi-
cacy before long-term effectiveness studies are pursued;
however, we believe that the feasibility of a longer-term
study is supported by our findings.
Additional file
Additional file 1: Trial interview data. (DOCX 16 kb)
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